Serotonin-selective reuptake inhibitors in the treatment of geriatric depression and related disorders

International Journal of Neuropsychopharmacology

Volumn 2, Issue 2, 1999, Pages 121-127

  Mulchahey, J Jeffrey ^a,b   Malik, Mohammad S ^b   Sabai, Mya ^b   Kasckow, John W ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Dementia; Depression; Geriatric; SSRI

Indexed keywords

EID: 0345271238     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001364     Document Type: Article

References (67)

1. Abernethy DR, Greenblatt DJ, Shader RI (1985). Imipramine and desipramine disposition in the elderly. Journal of Pharmacology and Experimental Therapeutics 232, 183-188.
2. Altamura AC, Percudani M, Guercetti G, Invernizzi G (1989). Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline. International Clinical Psychopharmacology 4 (Suppl. 1), 103-106.
3. Andersen G, Vestergaard K, Lauritzen L (1994). Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25, 1099-1104.
4. Anderson IM, Tomenson BM (1995). Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal 310, 1433-1438.
5. Baldwin RC, Jolley DJ (1986). The prognosis of depression in old age. British Journal of Psychiatry 149, 574-583.
6. Barbey JT, Roose SP (1998). SSRI safety in overdose. Journal of Clinical Psychiatry 59 (Suppl. 15), 42-48.
7. Baumann P, Larsen P (1995). The pharmacokinetics of citalopram. Reviews in Contemporary Pharmacotherapy 6, 287-195.
8. Bayer AJ, Pathy MS (1989). Identification of depression in geriatric medical patients. In: Ghose K (Ed.), Antidepressants for Elderly People (pp. 13-25). London: Chapman and Hall.
9. Benfield P, Ward A (1986). Fluvoxamine. A review of its phamacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32, 313-334.
10. Blazer D (1980). The diagnosis of depression in the elderly. Journal of the American Geriatric Society 28, 52-58.
11. Bouman WP, Pinner G, Johnson H (1998). Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatremia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. International Journal of Geriatric Psychiatry 13, 12-15.
12. Cohn CK, Shrivastava R, Mendel SJ, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TN, Lautin A (1990). Double-blind multicentre comparison of sertraline and amitriptyline in elderly depressed patients. Journal of Clinical Psychiatry 51 (Suppl. B), 28-33.
13. Cole MG (1990). The prognosis of depression in the elderly. Canadian Medical Association Journal 143, 633-639.
14. Cooper CL (1988). The safety of fluoxetine: an update. British Journal of Psychiatry (Suppl. 3), 77-86.
15. Dechant KL, Clissold SP (1991). Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41, 225-253.
16. Dorman T (1992). Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. International Clinical Psychopharmacology 6 (Suppl. 4), 53-58.
17. Dunner DL (1994). Therapeutic considerations in treating depression in the elderly. Journal of Clinical Psychiatry 55 (Suppl.), 48-58.
18. Dunner DL, Cohn JB, Walshe T, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EC Jr, Menolascino FJ, Muller DJ (1992). Two combined multicentre double-blind studies of paroxetine and doxepin in geriatric patients with major depression Journal of Clinical Psychiatry 53 (Suppl.), 57-60.
19. Falk WE, Rosenbaum JE, Otto MW, Zusky PM, Weilburg JB, Nixon RA (1989). Fluoxetine versus trazodone in depressed geriatric patients. Journal of Geriatric Psychiatry and Neurology 2, 208-214.
20. Feighner JP, Cohn JB (1985). Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. Journal of Clinical Psychiatry 46, 20-25.
21. Geldmacher DS, Waldman AJ, Doty L, Heilman KM (1994). Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition. Journal of Clinical Psychiatry 55, 161.
22. Georgotas A, McCue RE, Hapworth W, Friedman E, Kim OM, Welkowitz J, Chang I, Cooper TB (1986). Comparative efficacy and safety of MAOIs vs TCAs in treating depression in the elderly. Biological Psychiatry 21, 1155-1166.
23. Gottfries GG, Karlsson I, Nyth AL (1992). Treatment of depression in elderly patients with and without dementia disorders. International Clinical Psychopharmacology 6 (Suppl. 5), 55-64.
24. Grimsley SR, Jann MW (1992). Paroxetine, sertraline and fluvoxamine - new selective serotonin reuptake inhibitors. Clinical Pharmacology 11, 930-957.
25. Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y (1989). A double-blind multi-centre study of paroxetine vs clomipramine in depressed elderly patients. Acta Psychiatrica Scandanavica (Suppl. 350), 132-134.
26. Gutierrez MM (1997). Citalopram pharmacokinetics: a comparison between young and elderly subjects. American College of Neuropsychopharmacology Abstracts.
27. Haddad P (1997). Newer antidepressants and the discontinuation syndrome. Journal of Clinical Psychiatry 58 (Suppl. 7), 17-21.
28. Hakkarainen H (1998). Treatment-emergent adverse events in elderly depressed patients: doúble-blind comparison between citalopram and other selective serotonin reuptake inhibitors. American Psychiatric Association Meeting Abstracts.
29. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF (1990). Fluoxetine-induced sexual dysfunction. Journal of Clinical Psychiatry 51, 25-27.
30. Hindmarch I (1990). Antidepressants: the implications of the cognitive and psychomotor effects in the elderly. International Clinical Psychopharmacology 5 (Suppl. 3), 57-60.
31. Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A (1992). Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. International Clinical Psychopharmacology 6 (Suppl. 4), 43-51.
32. Jackson CW (1995). Obsessive-compulsive disorder in elderly patients. Drugs and Aging 7, 438-448.
33. Jalil P (1992). Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. Journal of Neurology, Neurosurgery and Psychiatry 55, 412-413.
34. Johnson J, Weissman MM, Klerman GL (1992). Service utilization and social morbidity associated with depressive symptoms in the community. Journal of the American Medical Association 267, 1478-1483.
35. Judd LL, Rapaport MH, Paulus MP, Brown JL (1994). Subsyndromal symptomatic depression: a new mood disorder? Journal of Clinical Psychiatry 55 (Suppl.), 18-28.
36. Kerr JS, Sherwood N, Hindmarch I (1991). The comparative Psychopharmacology of 5-HT re-uptake inhibitors. Human Psychopharmacology 6, 313-317.
37. Leo RJ (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 57, 449-454.
38. Montgomery SA (1993). New psychotropic drugs for the acute treatment of depressive disorders. In: Costa E, Silva JA, Nadelson CC (Eds.), International Review of Psychiatry (pp. 139-160). Washington, DC: American Psychiatric Press.
39. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D (1994a). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. International Clinical Psychopharmacology 9, 47-53.
40. Montgomery SA, Pedersen V, Tangjhoj P, Rasmussen C, Rioux P (1994b). The optimal dosing regime for citalopram: a meta-analysis of nine placebo-controlled studies. International Clinical Psychopharmacology 9 (Suppl. 1), 35-40.
41. Murray M (1992). P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmacokinetics 23, 132-146.
42. Nemeroff CB, DeVane CL, Pollock BG (1996). Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 153, 311-320.
43. Newhouse PA (1996). Use of serotonin selective reuptake inhibitors in geriatric depression. Journal of Clinical Psychiatry 57 (Suppl. 5), 12-22.
44. NIH Consensus Development Panel on Diagnosis and Treatment of Depression in Late Life (1992). Diagnosis and treatment of depression in late life. Journal of the American Medical Association 268, 1018-1024.
45. Nyth AL, Gottfries CG (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. British Journal of Psychiatry 157, 894-901.
46. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum HE, Ofsti E, Eriksson S, Syversen S (1992). A controlled muli-centre clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatrica Scandanavica 86, 138-145.
47. Olafsson K, Jorgensen S, Jensen HV, Bille A, Arup P, Andersen J (1992). Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study Acta Psychiatrica Scandanavica 85, 453-456.
48. Pollock BG (1994). Recent developments in drug metabolism of relevance to psychiatrists. Harvard Review of Psychiatry 2, 204-213.
49. Pollock BG, Mulsant BH, Sweet R, Burgio LD, Kirshner MA, Shuster K, Rosen J (1997). An open pilot study of citalopram for behavioral disturbances of dementia. American Journal of Geriatric Psychiatry 5, 70-78.
50. Preskorn SH (1993). Recent pharmacologic advances in antidepressant therapy for the elderly. American Journal of Medicine 94 (Suppl. 5A), 2S-12S.
51. Rasmussen SA, Eisen JL, Pato MT (1993). Current issues in t he pharmacologic management of obsessive compulsive disorder. Journal of Clinical Psychiatry 54 (Suppl.), 4-9.
52. Renshaw DC (1996). Sexuality and aging. In: Sadovoy J, Lazarus LW, Jarvik LF, Grossberg GP (Eds), Comprehensive Review of Geriatric Psychiatry II (pp. 713-729). Washington, DC: American Psychiatric Press.
53. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WR (1992). Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chemical Research in Toxicology 5, 54-59.
54. Richelson E (1994). Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clinic Proceedings 69, 1069-1081.
55. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry 44, 77-87.
56. Rowe JW (1980). Aging and renal function. Annual Review of Gerontological Geriatrics 1, 161-179.
57. Scates AN, Doraiswamy PM (1998). Focus on citalopram: a selective serotonin reuptake inhibitor for the treatment of depression. Formulary 33, 725-743.
58. Schone W, Ludwig M (1993). A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. Journal of Clinical Psychopharmacology 13 (6 Suppl. 2), 34S-39S.
59. Skerritt U, Evans R, Montgomery SA (1997). Selective serotonin reuptake inhibitors in older patients. A tolerability perspective. Drugs and Aging 10, 209-218.
60. Skjelbo E, Brosen K (1992). Inhibitors of imipramine metabolism by human liver microsomes. British Journal of Clinical Pharmacology 34, 256-261.
61. Smith DA (1991). Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drugs and Metabolism Reviews 23, 355-373.
62. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J (1993). Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal 306, 683-687.
63. Tariot PN (1996). Treatment strategies for agitation and psychosis in dementia. Journal of Clinical Psychiatry 57 (Suppl. 14), 21-29.
64. Tariot PN, Blazina L (1994). The psychopathology of dementia. In: Morris JC (Ed.), Handbook of Dementing Illnesses (pp. 461-475). New York: Marcel Dekker.
65. Tollefson GD, Holman SL (1993). Analysis of the Hamilton Depression Rating Scale factors from a double blind, placebo-controlled trial of fluoxetine in geriatric major depression. International Clinical Psychopharmacology 8, 253-259.
66. Wakelin JS (1986). Fluvoxamine in the treatment of the older depressed patient: double-blind placebo controlled data. International Clinical Psychopharmacology 1, 221-230.
67. Young RC, Meyers BS (1996). Psychopharmacology. In: Sadovoy J, Lazarus LW, Jarvik LF, Grossberg GP (Eds), Comprehensive Review of Geriatric Psychiatry II (pp. 755-817). Washington, DC: American Psychiatric Press.